TCGA-WA-A7GZ-01A-11R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.142694064
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.460
- E2F_TARGETS+0.360
- WNT_BETA_CATENIN_SIGNALING+0.310
- MYC_TARGETS_V1+0.280
- G2M_CHECKPOINT+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- DNA_REPAIR+0.190
- MYOGENESIS+0.090
- PANCREAS_BETA_CELLS+0.080
- MITOTIC_SPINDLE+0.010
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.470
- TNFA_SIGNALING_VIA_NFKB-0.450
- INFLAMMATORY_RESPONSE-0.440
- IL6_JAK_STAT3_SIGNALING-0.410
- INTERFERON_GAMMA_RESPONSE-0.400
- HYPOXIA-0.370
- PROTEIN_SECRETION-0.360
- APOPTOSIS-0.350
- COMPLEMENT-0.350
- IL2_STAT5_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_4D9DD103 | medulloblastoma | — | 0.889 |
| 2 | BS_K3ER45RV | medulloblastoma | — | 0.883 |
| 3 | SAMN03290896 | — | — | 0.883 |
| 4 | BS_2Z1MKS84 | medulloblastoma | — | 0.881 |
| 5 | BS_DBEX7AG2 | Embryonal tumors | — | 0.880 |
| 6 | C3N-00549 | — | cohortMD1 | 0.880 |
| 7 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.876 |
| 8 | SAMN03290918 | — | — | 0.876 |
| 9 | BS_JZRM1S3T | medulloblastoma | — | 0.873 |
| 10 | TCGA-46-6026-01A-11R-1820-07 | — | cohortSQ1 | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| MYOGENESIS | 0.090 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.010 | Inavolisib | — uncovered |